No Data
Hong Kong stock concept tracking | The end of medical insurance negotiations is very encouraging for innovative drugs to be included in medical insurance at reasonable prices (with concept stocks)
The on-site negotiation and bidding stages for the adjustment of the national medical insurance pharmaceutical catalog in 2024 officially ended recently.
Historically the most 'competitive'? The Tenth Batch of National Procurement Pharmaceutical Catalog Is Officially Announced with one type having up to 31 companies competing.
①This afternoon, the National Pharmaceutical Joint Procurement Office officially announced the tenth batch of nationally purchased pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Several industry insiders have stated that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
zheshang: Continuous realization of technological innovation upgrade driving the continuous improvement of performance expectations for innovative drugs and industry chain.
The commercialization period of innovative drugs in the industry chain, driven purely by incremental value, is entering the phase of realization. The scarce incremental prosperity of the pharmaceutical sector continues to rise, with increasing international competitiveness, and there is still room for upward valuation.
Hong Kong healthcare stocks receive attention from investors again, with Trifolium Biotech surging nearly 15%.
①What is the impact of medical insurance negotiations on pharmaceutical stocks? ②What are the reasons for the rise of Tri Clover Biopharmaceutical and Yimington Corporation?
new ray medic (06108.HK): Ho Chi Hung resigns as executive director
Graceful Alliances reported on October 16 that Mr. Huo Zhihong has resigned as an executive director and a member of the board of directors' Corporate Governance Committee of New Ray Medic (06108.HK) with effect from October 16, 2024, due to pursuing other business interests and commitments.
Express News | New Ray Medicine International - Huo Zhihong Resigned as an Executive Director
Investors Don't See Light At End Of New Ray Medicine International Holding Limited's (HKG:6108) Tunnel And Push Stock Down 34%No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}